Immunomodulators Flashcards

1
Q

monoclonal antibodies (mAb)

A

the drug product of a single B cell that is fused/hybridized with a multiple myeloma tumor cell →

you get a hybrid line that is immortal (like its tumor parent) but also make the specific antibody of its B cell parent (monoclonal antibodyproducing cells)! = Hybridoma →

After they make the Ab you want, you take it out of the well, and use it for your purposes→

mAb work by triggering ADCC (more on this in later objective)

5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Examples of monoclonal antibodies as anti-inflammatory agents.

A

Infliximab - chimeric Ab against TNFα → approved for a lot of inflammatory diseases

Tocilizumab - Anti IL-6 receptor → approved for RA (inflammation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Murine mAb

- suffix?

A

[-omab]

The first monoclonals made using B cells directly derived from immunized mice;

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Chimeric mAb

A

[-ximab]

mouse VL and VH domains (V regions)
human C domains

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Humanized mAb

A

[-zumab]

only the CDR’s of the V domains are from the mouse.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Fully human mAb

A

[-umab]

made entirely of human amino acids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

NK (natural killer) cells:

A

Large granular lymphocytes (LGL) which make up 5-10% of blood lymphocytic cells.

○ NK receptors recognize molecules on the surface of ‘stressed’ or dysregulated cells, such as virally-infected cells or many tumors, which they then kill; therefore, they are part of the innate immune system.

○ They have a second cytotoxic trick available: a special killing mechanism → ADCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How are NK cells different from CTLs?

A

○ NK cells are killers with mechanisms VERY similar to those of CTL, but they do not have rearranged V(D)J genes and are not thymic-derived.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Antibody-dependent cell-mediated cytotoxicity (ADCC):

A

Let’s take cells from a tumor that expresses markers that NK cells recognize via NK receptors → add antibodies (ie: IgG) that can bind to target tumor cells → no effect → add normal blood leukocytes (which include NK cells) → NK cells binds to the Fc end of the antibody → Just like a Killer T cells, NK cells trigger tumor cell death via delivery of lethal signals → induced apoptosis

(If you hadn’t added both antibody and the NK cells, nothing would have happened, so the phenomenon is called ADCC.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Whats unique about the way that ADCC work?

A

§ Anyone’s leukocytes can be used; the phenomenon is not MHC-restricted the way CTL-mediated killing is.

§ ADCC works because NK cells also have receptors for the Fc end of IgG (FcγR), and so they have a second, antibody-dependent, way to interact with target cells.

§ We know that many of the new therapeutic monoclonal antibodies (used to modulate the immune response, or treat cancer) work by triggering ADCC.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe how a monoclonal antibody against a T cell surface molecule could enhance the activity of a CTL.

A

Concept was named BiTE for Bispecific T-cell Engager. (Engages CTL)

-Couple together two single-chain engineered antibodies, one against CD19 and one against CD3 →
T cells can bind via their CD3 to CD19+ of B cell lymphoma cells.

This allows a transformed CTL to bind a tumor target with high affinity and chosen specificity, and, like an antibody, no MHC-restriction, and then be triggered via its normal TCR-associated pathway to become a fully-cytotoxic cell.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what type of mAb is it and what does it target?

- Rituximab

A
- Rituximab: chimeric mAb to CD20 
treat NH lymphoma, 
chronic lymphocytic leukemia 
RA when anti-TNF therapy fails 
off lable MS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Use of modified mAbs in tumor diagnosis + treatment

A

Ibritumomab:
murine mAb against CD20.
It helps chelate Indium and Ytrium and is first FDA approved radioimmunotherapy

mAb images the tumor, Ytrium treats it.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly